Moderna Stock Intrinsic Value – Moderna CEO Steps In As Commercial Chief Departs
December 18, 2023
🌥️Trending News
Moderna ($NASDAQ:MRNA), a biotechnology company based out of Cambridge, Massachusetts, has announced that their CEO, Stéphane Bancel, has stepped in to take on the responsibility of sales and marketing, following the departure of the company’s commercial chief. Moderna has become known for its innovative approach to developing treatments and vaccines for infectious diseases and cancer. Stéphane Bancel will be taking over the role of commercial chief, bringing with him a wealth of experience in sales and marketing from his time at Sanofi and Merck. He is credited with transforming Moderna’s product portfolio from small molecules to biologics and mRNA therapies.
With his guidance, the company has become a leader in the field of biotechnology. It is hoped that Stéphane Bancel will be able to provide the necessary support to ensure the vaccine is marketed correctly and efficiently. With his long history in the industry, there is no doubt he will be able to guide Moderna through this pivotal period.
Share Price
On Tuesday, the stock market saw a steep decline in the price of MODERNA shares. The stock opened at $81.2 and closed at $78.0, a decrease of 4.8%. This comes after news that MODERNA’s Chief Commercial Officer, Michael Mulroy, is departing the company.
In response to the announcement, MODERNA CEO Stephane Bancel has taken on the role of Chief Commercial Officer in order to ensure the successful transition of Mulroy’s responsibilities. The company has not yet made any further statements on potential replacement personnel. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Moderna. More…
| Total Revenues | Net Income | Net Margin |
| 9.19k | -3.47k | -37.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Moderna. More…
| Operations | Investing | Financing |
| -2.08k | 3.7k | -1.71k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Moderna. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 19.45k | 6k | 35.35 |
Key Ratios Snapshot
Some of the financial key ratios for Moderna are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 448.5% | – | -28.1% |
| FCF Margin | ROE | ROA |
| -28.9% | -10.6% | -8.3% |
Analysis – Moderna Stock Intrinsic Value
At GoodWhale, we have conducted an analysis of MODERNA‘s financials. Our proprietary Valuation Line has calculated the fair value of MODERNA share to be around $178.3. Currently, MODERNA stock is traded at $78.0, which is undervalued by a staggering 56.3%. This presents an excellent opportunity for investors to take advantage of the current market conditions and acquire MODERNA shares at a discounted price. We recommend investors to take a closer look at MODERNA’s financials and make an informed decision about investing in the company. More…
Peers
Moderna Inc is a biotechnology company that develops and manufactures drugs, vaccines, and diagnostics. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. Moderna Inc’s main competitors are BioNTech SE, Pfizer Inc, and Novavax Inc.
– BioNTech SE ($NASDAQ:BNTX)
BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 33.72B as of 2022 and a Return on Equity of 71.82%. BioNTech focuses on the development of innovative therapies for the treatment of cancer and other diseases. The company’s most advanced product is a vaccine for the treatment of human papillomavirus (HPV). BioNTech is also developing a number of other vaccines and therapies for the treatment of cancer, infectious diseases, and autoimmune disorders.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a global pharmaceutical company with a market cap of 247.45B as of 2022. The company’s return on equity is 24.63%. Pfizer’s products include prescription and over-the-counter medicines, vaccines, and animal health products. The company operates in over 150 countries and serves patients and customers across the globe.
– Novavax Inc ($NASDAQ:NVAX)
Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Novavax’s market cap as of 2022 is 1.46B and its ROE is 487.21%. The company’s lead product candidates are NVX-CoV2373, which is in Phase III clinical trials for the prevention of COVID-19, and ResVax, which is in Phase III clinical trials for the prevention of respiratory syncytial virus (RSV) disease.
Summary
Moderna‘s stock price took a dip the same day its Chief Commercial Officer stepped down.
However, the company’s CEO, Stephane Bancel, has now taken on the responsibility of leading both sales and marketing. Analysts believe this move signals Moderna’s confidence in its plans leading up to the commercialization of its products. Investors are hopeful that the company’s focus on driving new revenue streams will provide long-term value for its shareholders. The addition of Bancel to the commercial role is seen as a positive development, as he brings years of experience in drug development, manufacturing, and commercialization. With intense competition in the biopharmaceutical market, Moderna needs to remain focused on delivering innovative products to enhance shareholder value.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
